BioNTech’s $650 Million R&D Burn Reflects a Company Transformed, With ASCO as the Next Prove-It Moment

BioNTech posts Q1 net loss as it spends $650M on R&D, shareholders back oncology strategy, and pumitamig faces Keytruda at ASCO. Stock down 12.7%.

BioNTech enters a decisive week with roughly $20 billion in cash, a freshly expanded board, and a quarterly net loss that management is willing to accept as the price of remaking the company. The Mainz-based biotech spent more than $650 million on research and development in the first quarter of 2026, while revenue from its COVID-19 vaccine partnership with Pfizer amounted to just $138 million. The resulting red ink is by design: BioNTech is deliberately redirecting its pandemic windfall into an oncology pipeline it hopes will eventually dwarf its earlier success.

Shareholders gave a resounding endorsement of that strategy at the annual general meeting on May 15, where 92% of the capital stock was represented and every resolution passed. Among the key approvals were a new authorized capital scheme for 2026, an advisory vote on the compensation report, and an extension of the company’s ability to hold virtual meetings. More tellingly, investors backed a capital increase authorization that permits the issuance of new shares equal to up to 50% of existing capital. Given the ample cash pile, the move is widely seen as strategic ammunition for future acquisitions or partnerships rather than a sign of distress.

The board itself was restructured to reflect the oncology pivot. BioNTech expanded its supervisory board from six to eight seats, electing Prof. Iris Löw-Friedrich and Susanne Schaffert. Löw-Friedrich brings deep experience in clinical development and international markets, while Schaffert already serves on the supervisory board of Merck KGaA and other healthcare companies. Their appointments complement the reappointment of incumbents Helmut Jeggle, Anja Morawietz, and Rudolf Staudigl. Jeggle was subsequently elected chairman, blending continuity with new expertise for the later-stage pipeline ahead.

CEO Ugur Sahin, who indicated this was likely his last annual meeting speech at the helm, reiterated the dual mandate: continue the COVID-19 vaccine business with Pfizer while funneling proceeds into a broad oncology pipeline. The company is targeting 15 Phase 3 studies by the end of 2026 and expects seven late-stage data readouts this year alone. More than 25 Phase 2/3 trials are already running across 17 clinical programs. The lead candidate, pumitamig, is set to take center stage at the American Society of Clinical Oncology (ASCO) annual meeting, which runs from May 29 to June 2. On the first day of the conference, BioNTech will present Phase 2 data from the ROSETTA-Lung-02 study, in which pumitamig goes head-to-head against Merck & Co’s Keytruda (pembrolizumab)—the current standard of care in first-line non-small cell lung cancer. A favorable result could fundamentally shift how the market views BioNTech’s entire oncology pipeline.

The stock, however, reflects caution rather than optimism. Shares recently traded at €75.95, down 1.3% on the day and 12.7% over the past 30 days. That leaves the company 11% below its level a year ago and far from the 52-week high of €101.90 set in the summer of 2025. Technical indicators show the stock under key moving averages and only modestly above its recent low.

Operationally, the company is also streamlining. Future clinical production of mRNA-based candidates will run through a broader network including its Mainz facility, while commercial COVID-19 vaccine manufacturing is expected to transition fully to Pfizer by the end of 2026. This frees BioNTech to concentrate resources on what really matters now: turning a pipeline of promising oncology assets into a new revenue engine starting perhaps as early as the ASCO data readout in a few days.